임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

6건 표시

• 임상
  2상모집 예정· Phase 2 Study

  Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia

  협력: 암젠

  상세 →NCT07192237
• 임상
  2상모집 예정· Phase II Clinical Trial

  Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

  협력: 암젠

  상세 →NCT07178912
• 임상
  2상모집 예정· Immunoglobulin G4-related Disease

  Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD

  리드: 암젠

  상세 →NCT07222553
• 임상
  2상모집 예정· Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)

  Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL

  협력: 암젠

  상세 →NCT07301424
• 임상
  2상모집 예정· Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma

  Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)

  협력: 암젠

  상세 →NCT06816394
• 임상
  2상모집 예정· Treatment Related Cancer

  Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

  협력: 암젠

  상세 →NCT04034173

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.